PE20121642A1 - Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura - Google Patents
Sales de timo depresores farmaceuticamente aceptables y procesos para su manufacturaInfo
- Publication number
- PE20121642A1 PE20121642A1 PE2012000979A PE2012000979A PE20121642A1 PE 20121642 A1 PE20121642 A1 PE 20121642A1 PE 2012000979 A PE2012000979 A PE 2012000979A PE 2012000979 A PE2012000979 A PE 2012000979A PE 20121642 A1 PE20121642 A1 PE 20121642A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutically acceptable
- crystalline
- formula
- thimo
- depressors
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- HJFJVGRAUAAGDP-WLDMJGECSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-(methylamino)oxane-3,4,5-triol Chemical compound CNC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HJFJVGRAUAAGDP-WLDMJGECSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910052744 lithium Chemical group 0.000 abstract 1
- 229910003002 lithium salt Inorganic materials 0.000 abstract 1
- 159000000002 lithium salts Chemical class 0.000 abstract 1
- 239000011777 magnesium Chemical group 0.000 abstract 1
- 229910052749 magnesium Chemical group 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-O tert-butylammonium Chemical compound CC(C)(C)[NH3+] YBRBMKDOPFTVDT-UHFFFAOYSA-O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
REFERIDA A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE D-ISOGLUTAMIL-D-TRIPTOFANO DE FORMULAS (I), (II) Y (III), EN SUS FORMAS AMORFAS O CRISTALINAS. PARA LA FORMULA (I), M ES POTASIO O LITIO, DONDE PARA LA SAL CRISTALINA DE POTASIO SE PRESENTA UN PATRON DE DIFRACCION DE RAYOS X EN POLVO PARA VALORES 2-THETA DE 9,91, 14,84, 15,81, 18,97, 19,76, 24,04, 24,36, 24,82, 25,48, 27,49, 27,94, 28,42, 30,82, 31,28, 31,69, 32,17, 34,35, 35,81 Y 36,96, Y PÀRA LA SAL CRISTALINA DE LITIO PRESENTA PICOS DE 13,57, 15,53, 18,71, 20,11, 23,34, 24,1, 25,09, 27,31, 27,72, 28,39, 29,31, 30,19, 31,21, 32,06, 33,05, 33,62 Y 37,41. PARA LA FORMULA (II), B ES CALCIO O MAGNESIO, DONDE PARA LA SAL CRISTALINA DE MAGNESIO PRESENTA PICOS DE 12,2, 13,74, 14,84, 16,16, 17,96, 18,52, 18,94, 19,49, 21,05, 21,56, 22,56, 23,36, 24,12, 26,27, 27,65, 28,42, 29,14, 30,55, 31,77, 32,62, 33,26, 35,05, 36,34, 37,22 Y 38,05. PARA LA FORMULA (III), A ES TERT-BUTILAMONIO, TRIS(HIDROXIMETIL)METILAMONIO O N-METIL-D-GLUCOSILAMONIO. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002571645A CA2571645A1 (en) | 2006-12-19 | 2006-12-19 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121642A1 true PE20121642A1 (es) | 2012-12-16 |
Family
ID=39535926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001794A PE20081402A1 (es) | 2006-12-19 | 2007-12-14 | Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura |
| PE2012000979A PE20121642A1 (es) | 2006-12-19 | 2007-12-14 | Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001794A PE20081402A1 (es) | 2006-12-19 | 2007-12-14 | Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8138221B2 (es) |
| EP (1) | EP2121729A4 (es) |
| KR (1) | KR20090108034A (es) |
| CN (2) | CN103554004A (es) |
| AU (1) | AU2007335212B2 (es) |
| CA (2) | CA2571645A1 (es) |
| CL (1) | CL2007003680A1 (es) |
| MX (1) | MX2009006673A (es) |
| PE (2) | PE20081402A1 (es) |
| RU (1) | RU2536685C2 (es) |
| TW (1) | TWI406872B (es) |
| UA (1) | UA106580C2 (es) |
| UY (1) | UY30798A1 (es) |
| WO (1) | WO2008074128A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2579119C (en) | 2007-02-16 | 2013-03-05 | Apotex Technologies Inc. | Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| RU2634258C1 (ru) * | 2016-11-08 | 2017-10-24 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Наполнитель для капсульного ингалятора |
| RU2703991C1 (ru) * | 2019-02-12 | 2019-10-23 | Акционерное общество "Медико-биологический научно-производственный комплекс "Цитомед" (АО "МБНПК "Цитомед") | Способ получения мононатриевой соли изоглутамил-триптофана |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3238118A1 (de) | 1982-10-14 | 1984-04-19 | Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing | Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen |
| GB2152031B (en) * | 1984-01-10 | 1987-07-22 | Mitsui Toatsu Chemicals | Separating l-tryptophan from fermentation broth |
| US5902790A (en) * | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| RU2107692C1 (ru) * | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| RU2107691C1 (ru) * | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| US6103699A (en) * | 1996-06-07 | 2000-08-15 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| DE19540788A1 (de) * | 1995-11-02 | 1997-05-07 | Degussa | Verwendung von wässrigen L-Tryptophan- und/oder L-Threonin-Salzlösungen |
| US5916878A (en) * | 1995-11-28 | 1999-06-29 | Edward T. Wei | γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith |
| US5744452A (en) * | 1995-11-28 | 1998-04-28 | Edward T. Wei | γ-L-glutamyl containing immunomodulator compounds and methods therewith |
| IL120923A0 (en) | 1997-05-27 | 1997-09-30 | Amylum Nv | A combined process for the production of lysine and its salts and of a further weak acid and a salt thereof |
| EP2046778B1 (en) * | 2006-08-04 | 2013-12-04 | Manus Pharmaceuticals (Canada) Ltd. | Multifunctional bioactive compounds |
| CA2569204A1 (en) * | 2006-11-28 | 2008-05-28 | Apotex Technologies Inc. | Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan |
-
2006
- 2006-12-19 CA CA002571645A patent/CA2571645A1/en not_active Abandoned
-
2007
- 2007-12-13 TW TW096147768A patent/TWI406872B/zh not_active IP Right Cessation
- 2007-12-13 US US12/520,337 patent/US8138221B2/en not_active Expired - Fee Related
- 2007-12-13 EP EP07855517.4A patent/EP2121729A4/en not_active Withdrawn
- 2007-12-13 CN CN201310459336.XA patent/CN103554004A/zh active Pending
- 2007-12-13 RU RU2009127795/04A patent/RU2536685C2/ru not_active IP Right Cessation
- 2007-12-13 WO PCT/CA2007/002235 patent/WO2008074128A1/en active Application Filing
- 2007-12-13 AU AU2007335212A patent/AU2007335212B2/en not_active Ceased
- 2007-12-13 CN CN2007800508835A patent/CN101611050B/zh not_active Expired - Fee Related
- 2007-12-13 CA CA002673421A patent/CA2673421A1/en not_active Abandoned
- 2007-12-13 UA UAA200907340A patent/UA106580C2/uk unknown
- 2007-12-13 MX MX2009006673A patent/MX2009006673A/es active IP Right Grant
- 2007-12-13 KR KR1020097014834A patent/KR20090108034A/ko not_active Application Discontinuation
- 2007-12-14 UY UY30798A patent/UY30798A1/es not_active Application Discontinuation
- 2007-12-14 PE PE2007001794A patent/PE20081402A1/es not_active Application Discontinuation
- 2007-12-14 PE PE2012000979A patent/PE20121642A1/es not_active Application Discontinuation
- 2007-12-18 CL CL200703680A patent/CL2007003680A1/es unknown
-
2012
- 2012-03-19 US US13/424,343 patent/US8735602B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UY30798A1 (es) | 2008-07-03 |
| AU2007335212B2 (en) | 2013-09-05 |
| UA106580C2 (uk) | 2014-09-25 |
| KR20090108034A (ko) | 2009-10-14 |
| RU2536685C2 (ru) | 2014-12-27 |
| CN101611050B (zh) | 2013-10-30 |
| PE20081402A1 (es) | 2008-11-16 |
| US20130072692A1 (en) | 2013-03-21 |
| EP2121729A4 (en) | 2013-07-31 |
| US8138221B2 (en) | 2012-03-20 |
| MX2009006673A (es) | 2009-11-02 |
| CL2007003680A1 (es) | 2008-03-14 |
| TW200833708A (en) | 2008-08-16 |
| RU2009127795A (ru) | 2011-01-27 |
| EP2121729A1 (en) | 2009-11-25 |
| TWI406872B (zh) | 2013-09-01 |
| US20100056803A1 (en) | 2010-03-04 |
| CA2571645A1 (en) | 2008-06-19 |
| CN101611050A (zh) | 2009-12-23 |
| AU2007335212A1 (en) | 2008-06-26 |
| CN103554004A (zh) | 2014-02-05 |
| CA2673421A1 (en) | 2008-06-26 |
| WO2008074128A1 (en) | 2008-06-26 |
| US8735602B2 (en) | 2014-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300731A2 (hu) | Valzartan-sók, eljárás elżállításukra és az azokat tartalmazó gyógyszerkészítmények | |
| ES2550003T3 (es) | Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones | |
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| PE20121642A1 (es) | Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura | |
| RU2013109393A (ru) | Безилатная соль ингибитора втк | |
| ES2543804T3 (es) | Polimorfo B de Ibandronato | |
| GEP20105086B (en) | Potassium salt of an hiv integrase inhibitor | |
| WO2006023515A3 (en) | Novel thiazole inhibitors of fructose 1,6-bisphosphatase | |
| RS51210B (sr) | Dobijanje pregaballina i srodnih jedinjenja | |
| AR068086A2 (es) | Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos | |
| PE20081157A1 (es) | Forma cristalina de hemifumarato de alisquireno | |
| AR034259A1 (es) | Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen | |
| ECSP099818A (es) | Procesos para la preparacion de pirazoles | |
| TN2011000231A1 (fr) | Nouvelle composition a base d'acide gamma-hydroxybutyrique | |
| PE20120361A1 (es) | Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico | |
| EA200601963A1 (ru) | Соли дигидрожасмоновой кислоты и их применение в сельском хозяйстве | |
| CY1117753T1 (el) | Κρυσταλλικη μορφη του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν | |
| ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| AR060838A1 (es) | Formulaciones de dosificacion solida | |
| MX2009010699A (es) | Nuevos metodos. | |
| EA200900732A1 (ru) | Кристаллическая калиевая соль аналогов липоксина а | |
| AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
| CO6270318A2 (es) | Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465 | |
| PE20081167A1 (es) | Sal de alisquireno | |
| PE20212197A1 (es) | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |